Cell-Penetrating Peptide Nanoparticles Deliver Cancer Drug Methotrexate Directly to CD44+ Tumor Cells
Hyaluronic acid-coated branched cell-penetrating peptide nanoparticles delivered methotrexate selectively to CD44-overexpressing cancer cells with glutathione-triggered drug release and superior in vivo tumor inhibition.
Quick Facts
What This Study Found
B-mR9-MTX/HA nanoparticles demonstrated glutathione-triggered degradability, CD44-mediated cancer cell targeting, efficient intracellular methotrexate delivery, and superior tumor inhibition in vivo.
Key Numbers
B-mR9/HA nanoparticles achieved selective CD44-mediated uptake and redox-triggered MTX release in cancer cells.
How They Did This
Synthesis of branched modified nona-arginine (B-mR9) with redox-cleavable disulfide bonds. Methotrexate loading and hyaluronic acid coating. In vitro CD44-mediated uptake studies. In vivo tumor inhibition study.
Why This Research Matters
Targeted drug delivery could improve cancer treatment by getting more drug to tumor cells while reducing side effects. Using cell-penetrating peptides as the delivery backbone adds the ability to enter cells efficiently, while the targeting and triggered-release features add specificity.
The Bigger Picture
Smart nanoparticles that combine targeting, cell penetration, and triggered drug release represent the cutting edge of drug delivery. This peptide-based platform addresses multiple challenges simultaneously — toxicity, specificity, and efficacy — in a single nanomedicine design.
What This Study Doesn't Tell Us
Early-stage in vivo data without detailed pharmacokinetics or toxicity profiles. CD44 is expressed on some normal cells, potentially causing off-target effects. Manufacturing complexity of multi-component nanoparticles may limit clinical translation.
Questions This Raises
- ?Can this platform be adapted for other chemotherapy drugs beyond methotrexate?
- ?How does the pharmacokinetic profile compare to standard methotrexate formulations?
- ?What is the long-term safety profile of B-mR9 degradation products?
Trust & Context
- Key Stat:
- CD44-mediated targeting of cancer cells through hyaluronic acid coating on cell-penetrating peptide nanoparticles
- Evidence Grade:
- Proof-of-concept with both in vitro targeting confirmation and in vivo tumor inhibition. Early-stage but demonstrates multi-functional nanomedicine design.
- Study Age:
- Published in 2020. Peptide-based nanomedicine for targeted cancer therapy continues to be actively developed.
- Original Title:
- CD44-Mediated Methotrexate Delivery by Hyaluronan-Coated Nanoparticles Composed of a Branched Cell-Penetrating Peptide.
- Published In:
- ACS biomaterials science & engineering, 6(1), 494-504 (2020)
- Authors:
- Yoo, Jisang, Rejinold, N Sanoj, Lee, DaeYong, Noh, Ilkoo, Koh, Won-Gun, Jon, Sangyong, Kim, Yeu-Chun
- Database ID:
- RPEP-05223
Evidence Hierarchy
Frequently Asked Questions
What makes these nanoparticles 'smart'?
They combine three intelligent features: hyaluronic acid targeting to find cancer cells (via CD44), cell-penetrating peptides to enter cells efficiently, and redox-responsive bonds that release the drug only inside cancer cells.
Why use cell-penetrating peptides in nanoparticles?
Cell-penetrating peptides help nanoparticles cross cell membranes efficiently, ensuring the cancer drug gets inside cells rather than just sticking to the surface or floating past.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05223APA
Yoo, Jisang; Rejinold, N Sanoj; Lee, DaeYong; Noh, Ilkoo; Koh, Won-Gun; Jon, Sangyong; Kim, Yeu-Chun. (2020). CD44-Mediated Methotrexate Delivery by Hyaluronan-Coated Nanoparticles Composed of a Branched Cell-Penetrating Peptide.. ACS biomaterials science & engineering, 6(1), 494-504. https://doi.org/10.1021/acsbiomaterials.9b01724
MLA
Yoo, Jisang, et al. "CD44-Mediated Methotrexate Delivery by Hyaluronan-Coated Nanoparticles Composed of a Branched Cell-Penetrating Peptide.." ACS biomaterials science & engineering, 2020. https://doi.org/10.1021/acsbiomaterials.9b01724
RethinkPeptides
RethinkPeptides Research Database. "CD44-Mediated Methotrexate Delivery by Hyaluronan-Coated Nan..." RPEP-05223. Retrieved from https://rethinkpeptides.com/research/yoo-2020-cd44mediated-methotrexate-delivery-by
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.